Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at $24,960,240.32. The trade was a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded up $8.76 during trading hours on Thursday, reaching $555.91. The company had a trading volume of 531,986 shares, compared to its average volume of 498,740. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The business has a fifty day simple moving average of $559.06 and a 200 day simple moving average of $527.20. The firm has a market cap of $23.60 billion, a PE ratio of 20.52, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $6.63 earnings per share. On average, research analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current year.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. UBS Group boosted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $619.42.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Versant Capital Management Inc increased its position in shares of United Therapeutics by 93.6% in the second quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 88 shares during the last quarter. Pacer Advisors Inc. lifted its position in United Therapeutics by 0.7% during the first quarter. Pacer Advisors Inc. now owns 243,545 shares of the biotechnology company’s stock valued at $144,417,000 after purchasing an additional 1,673 shares during the last quarter. Parallel Advisors LLC grew its stake in United Therapeutics by 2.8% in the 1st quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company’s stock worth $626,000 after buying an additional 29 shares in the last quarter. NewEdge Advisors LLC grew its stake in United Therapeutics by 24.7% in the 1st quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company’s stock worth $1,283,000 after buying an additional 428 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.